Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia)

Paper Submission

Google-based Impact Factor: 0.83 Citations
h5-index & Ranking*

"Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia)"
written by Zahra Mozaheb, Maeedeh Javani,
published by Health, Vol.6 No.10, 2014

has been cited by the following article(s):

[1]	Tyrosine Kinas Inhibitor and Fertility
	2018

[2]	Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
	Journal of Applied Pharmaceutical Science Vol, 2015

[3]	Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
	Journal of Applied Pharmaceutical Science (JAPS), 2015